FDA Greenlights Enhertu for Advanced HER2-Positive Tumors – The Babak Lab
Maria Babak shared a post by
“Incredible news for the oncology community and patients everywhere! The FDA’s accelerated approval of Enhertu is a game-changer for those battling unresectable or metastatic HER2-positive tumors.
This innovative treatment brings new hope and possibilities for patients who previously had limited treatment options. Congratulations to all involved in making this breakthrough possible!”
Quoting
“Clinical Monday: FDA Greenlights Enhertu for Advanced HER2-Positive Tumors!
Source: Maria Babak/LinkedIn and The Babak Lab/LinkedIn
Dr. Maria (Masha) Babak is the Head of The Babak Lab and an Assistant Professor at the City University of Hong Kong. She earned her Ph.D. in bioinorganic chemistry from the University of Vienna in 2014. From 2015 to 2020, Dr. Babak was a postdoctoral research fellow at the National University of Singapore under the mentorship of Prof.
Wee Han Ang, where she developed a strong passion for drug discovery and drug target identification. In November 2020, she joined the City University of Hong Kong as an assistant professor. Dr. Babak received the Graeme Hanson-AsBIC Early Career Award in 2022.
Her research interests are at the intersection of chemistry, biology, and medicine, with a focus on the discovery and preclinical development of anticancer drugs for resistant and aggressive cancers with limited treatment options, such as malignant pleural mesothelioma and brain metastases.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
– New Hope for Patients: Offers a vital treatment option for those with challenging HER2-positive tumors.
– Promising Results: Clinical trials showed objective response rates of up to 52.9%.
– Patient Safety: Be mindful of serious risks like interstitial lung disease and embryo-fetal toxicity.Key Details:
– Dosage: 5.4 mg/kg IV infusion every three weeks.
– Continued Approval: Dependent on further trials to confirm clinical benefits.
This approval marks a significant advancement in personalized cancer treatment, providing new hope for improved patient outcomes.”